ES2683372T3 - Derivados de GLP-1 acilados con un conector nuevo - Google Patents
Derivados de GLP-1 acilados con un conector nuevo Download PDFInfo
- Publication number
- ES2683372T3 ES2683372T3 ES11779674T ES11779674T ES2683372T3 ES 2683372 T3 ES2683372 T3 ES 2683372T3 ES 11779674 T ES11779674 T ES 11779674T ES 11779674 T ES11779674 T ES 11779674T ES 2683372 T3 ES2683372 T3 ES 2683372T3
- Authority
- ES
- Spain
- Prior art keywords
- glp
- integer
- range
- residue
- acylated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title abstract 2
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 abstract 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 2
- 150000001408 amides Chemical class 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Reproductive Health (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190515 | 2010-11-09 | ||
| US41422110P | 2010-11-16 | 2010-11-16 | |
| EP11169276 | 2011-06-09 | ||
| US201161497123P | 2011-06-15 | 2011-06-15 | |
| PCT/EP2011/069743 WO2012062804A1 (en) | 2010-11-09 | 2011-11-09 | Double-acylated glp-1 derivatives with a linker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2683372T3 true ES2683372T3 (es) | 2018-09-26 |
Family
ID=46050422
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11779674T Active ES2683372T3 (es) | 2010-11-09 | 2011-11-09 | Derivados de GLP-1 acilados con un conector nuevo |
| ES11779456T Active ES2913803T3 (es) | 2010-11-09 | 2011-11-09 | Derivados de GLP-1 diacilados |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11779456T Active ES2913803T3 (es) | 2010-11-09 | 2011-11-09 | Derivados de GLP-1 diacilados |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US9708383B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2637699B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6231386B2 (cg-RX-API-DMAC7.html) |
| CN (3) | CN103209711B (cg-RX-API-DMAC7.html) |
| ES (2) | ES2683372T3 (cg-RX-API-DMAC7.html) |
| WO (2) | WO2012062804A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5750341A (en) | 1995-04-17 | 1998-05-12 | Lynx Therapeutics, Inc. | DNA sequencing by parallel oligonucleotide extensions |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| WO2012062804A1 (en) * | 2010-11-09 | 2012-05-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives with a linker |
| JP6126097B2 (ja) | 2011-09-06 | 2017-05-10 | ノヴォ ノルディスク アー／エス | Ｇｌｐ−１誘導体 |
| KR102184241B1 (ko) | 2012-05-03 | 2020-12-01 | 질랜드 파마 에이/에스 | Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법 |
| ES2629735T3 (es) * | 2012-05-08 | 2017-08-14 | Novo Nordisk A/S | Derivados de GLP-1 doblemente acilados |
| JP6250034B2 (ja) | 2012-05-08 | 2017-12-20 | ノヴォ ノルディスク アー／エス | 二重アシル化されたｇｌｐ−１誘導体 |
| ES2620111T3 (es) | 2012-07-23 | 2017-06-27 | Zealand Pharma A/S | Análogos de glucagón |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| WO2014199397A2 (en) * | 2013-06-11 | 2014-12-18 | Mylan Laboratories Ltd | Process for the preparation of liraglutide |
| ES2646538T3 (es) | 2013-06-20 | 2017-12-14 | Novo Nordisk A/S | Derivados de GLP-1 y sus usos |
| BR112015032875A2 (pt) | 2013-07-04 | 2017-11-07 | Novo Nordisk As | derivados de peptídeos do tipo glp-1, e usos dos mesmos |
| CN105451776B (zh) * | 2013-08-15 | 2020-04-17 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| US9896495B2 (en) | 2013-10-17 | 2018-02-20 | Zealand Pharma A/S | Acylated glucagon analogues |
| CA2929107C (en) | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
| AU2014345569B2 (en) | 2013-11-06 | 2020-08-13 | Zealand Pharma A/S | GIP-GLP-1 dual agonist compounds and methods |
| US10221315B2 (en) * | 2013-11-08 | 2019-03-05 | Ppg Industries Ohio, Inc. | Curable film-forming composition comprising catalyst associated with a carrier |
| WO2015155151A1 (en) * | 2014-04-07 | 2015-10-15 | Novo Nordisk A/S | Double-acylated glp-1 compounds |
| MX381640B (es) | 2014-10-29 | 2025-03-04 | Zealand Pharma As | Metodos y compuestos agonistas de gip. |
| ES2739289T3 (es) | 2014-11-27 | 2020-01-30 | Novo Nordisk As | Derivados de GLP-1 y sus usos |
| CN107108714B (zh) * | 2014-12-17 | 2022-02-08 | 诺和诺德股份有限公司 | Glp-1衍生物及其用途 |
| ES2763329T3 (es) | 2015-04-16 | 2020-05-28 | Zealand Pharma As | Análogo de glucagón acilado |
| AU2016270373A1 (en) | 2015-06-05 | 2018-01-04 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2019023295A1 (en) * | 2017-07-27 | 2019-01-31 | Saint Louis University | Fatty acid modified human epidermal growth factor |
| TWI847306B (zh) | 2017-08-24 | 2024-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | Ｇｌｐ-１組成物及其用途 |
| HUE067499T2 (hu) | 2018-04-05 | 2024-10-28 | Sun Pharmaceutical Ind Ltd | Új GLP-1 analógok |
| CN113214382B (zh) * | 2018-04-19 | 2024-01-19 | 杭州先为达生物科技股份有限公司 | 酰化的glp-1衍生物 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| GB201813678D0 (en) * | 2018-08-22 | 2018-10-03 | Keybioscience Ag | Acylated calcitonin mimetics |
| CN115260313B (zh) | 2019-12-31 | 2023-07-18 | 北京质肽生物医药科技有限公司 | Glp-1和gdf15的融合蛋白以及其缀合物 |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| WO2022068920A1 (en) | 2020-09-30 | 2022-04-07 | Beijing Ql Biopharmaceutical Co., Ltd. | Polypeptide conjugates and methods of uses |
| EP4240420A1 (en) | 2020-11-06 | 2023-09-13 | Novo Nordisk A/S | Glp-1 prodrugs and uses hereof |
| CA3220333A1 (en) | 2021-05-18 | 2022-11-24 | Musashino University | Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent |
| WO2022266927A1 (zh) * | 2021-06-24 | 2022-12-29 | 深圳翰宇药业股份有限公司 | 一种利拉鲁肽变构体及其制备方法、应用 |
| JP2025512832A (ja) | 2022-03-30 | 2025-04-22 | ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド | ポリペプチドコンジュゲートの液体医薬組成物およびその使用の方法 |
| WO2023217744A1 (en) | 2022-05-10 | 2023-11-16 | Novo Nordisk A/S | Prodrugs of glp-1 polypeptide and uses thereof |
| EP4642440A1 (en) | 2022-12-30 | 2025-11-05 | Algipharma As | Compositions and methods to increase the systemic bioavailability of a polypeptide therapeutic agent undergoing oral administration |
| CN120676965A (zh) * | 2023-11-07 | 2025-09-19 | 深圳信立泰药业股份有限公司 | 多重受体共激动剂化合物及其制备方法与应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5336782A (en) | 1991-04-24 | 1994-08-09 | Kuraray Co., Ltd. | Long chain carboxylic acid imide ester |
| SE9102652D0 (sv) * | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5512549A (en) * | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| DE69737479T4 (de) | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | Glp-1 derivate |
| ATE466027T1 (de) * | 1998-02-27 | 2010-05-15 | Novo Nordisk As | Abkömmlinge von glp-1 analogen |
| MY155270A (en) * | 1998-09-24 | 2015-09-30 | Lilly Co Eli | Use of glp-1 or analogs in treatment of stroke |
| JP4949838B2 (ja) | 2003-09-19 | 2012-06-13 | ノヴォ ノルディスク アー／エス | 新規ｇｌｐ−１誘導体 |
| EP1846446B1 (en) | 2005-02-02 | 2013-06-26 | Novo Nordisk A/S | Insulin derivatives |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| JP2011504871A (ja) | 2007-06-01 | 2011-02-17 | ノボ・ノルデイスク・エー／エス | 固体又は半固体担体中にペプチド薬剤を含む自然に分散可能なプレコンセントレイト |
| WO2009030738A1 (en) | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
| WO2009042922A2 (en) | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
| US20100317057A1 (en) * | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| CN102149411A (zh) | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
| CN102791731B (zh) | 2009-12-16 | 2016-04-20 | 诺沃—诺迪斯克有限公司 | Glp-1类似物和衍生物 |
| WO2012062804A1 (en) * | 2010-11-09 | 2012-05-18 | Novo Nordisk A/S | Double-acylated glp-1 derivatives with a linker |
-
2011
- 2011-11-09 WO PCT/EP2011/069743 patent/WO2012062804A1/en not_active Ceased
- 2011-11-09 CN CN201180054077.1A patent/CN103209711B/zh active Active
- 2011-11-09 CN CN201610182509.1A patent/CN105601729A/zh not_active Withdrawn
- 2011-11-09 US US13/882,947 patent/US9708383B2/en active Active
- 2011-11-09 EP EP11779674.8A patent/EP2637699B1/en active Active
- 2011-11-09 US US13/883,946 patent/US9006178B2/en active Active
- 2011-11-09 EP EP11779456.0A patent/EP2637698B1/en active Active
- 2011-11-09 JP JP2013538180A patent/JP6231386B2/ja active Active
- 2011-11-09 ES ES11779674T patent/ES2683372T3/es active Active
- 2011-11-09 ES ES11779456T patent/ES2913803T3/es active Active
- 2011-11-09 CN CN201180054105.XA patent/CN103200966B/zh active Active
- 2011-11-09 JP JP2013538179A patent/JP6039569B2/ja active Active
- 2011-11-09 WO PCT/EP2011/069738 patent/WO2012062803A1/en not_active Ceased
-
2015
- 2015-01-29 US US14/608,284 patent/US20150210745A1/en not_active Abandoned
-
2016
- 2016-08-01 JP JP2016151098A patent/JP2016188246A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US20130288960A1 (en) | 2013-10-31 |
| US9708383B2 (en) | 2017-07-18 |
| CN105601729A (zh) | 2016-05-25 |
| JP2014501712A (ja) | 2014-01-23 |
| EP2637698A1 (en) | 2013-09-18 |
| US20130338068A1 (en) | 2013-12-19 |
| ES2913803T3 (es) | 2022-06-06 |
| US20150210745A1 (en) | 2015-07-30 |
| US9006178B2 (en) | 2015-04-14 |
| CN103209711A (zh) | 2013-07-17 |
| EP2637699A1 (en) | 2013-09-18 |
| EP2637699B1 (en) | 2018-05-16 |
| CN103200966A (zh) | 2013-07-10 |
| JP6231386B2 (ja) | 2017-11-15 |
| WO2012062804A1 (en) | 2012-05-18 |
| JP6039569B2 (ja) | 2016-12-07 |
| EP2637698B1 (en) | 2022-04-20 |
| CN103200966B (zh) | 2016-10-12 |
| JP2016188246A (ja) | 2016-11-04 |
| JP2013543853A (ja) | 2013-12-09 |
| CN103209711B (zh) | 2016-04-13 |
| WO2012062803A1 (en) | 2012-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2683372T3 (es) | Derivados de GLP-1 acilados con un conector nuevo | |
| DOP2020000062A (es) | Procedimiento para la preparación de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
| HRP20220455T1 (hr) | Modificirane aminokiseline koje sadrže azid grupu | |
| AR080904A2 (es) | Coagonistas del receptor de glucagon /glp - 1 | |
| IL258253A (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
| AR059300A1 (es) | Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas | |
| BRPI0923346A2 (pt) | Proteinas em super-helice antiparalela de cadeia simples | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| MX2013011674A (es) | Derivados de peptido 1 tipo glucagon (glp-1) doblemente acilados. | |
| WO2009087082A3 (de) | Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil | |
| IN2014DN09922A (cg-RX-API-DMAC7.html) | ||
| MX353720B (es) | Moleculas analogas de ciclosporina modificadas en el aminoacido 1 y 3. | |
| PE20130326A1 (es) | Analogos de glucagon | |
| AR070633A1 (es) | Metodos para modificar el punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en la region de determinacion de la complementariedad (cdr) | |
| UA109949C2 (uk) | Композиція і лікарський засіб, які містять ідуронат-2-сульфатазу, і спосіб їх отримання | |
| EA201170879A1 (ru) | Полипептиды с ксиланазной активностью | |
| NO20082510L (no) | En fremgangsmate for konsentrasjon av et polypeptid | |
| PT2310356E (pt) | Derivados de adamantildiamida e a sua utilização | |
| CO6260099A2 (es) | Depsipeptidos ciclicos | |
| EA201001722A1 (ru) | Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции | |
| PE20211497A1 (es) | Conjugados de farmaco y anticuerpo anti-sez6 y metodos de uso | |
| EA201270790A1 (ru) | Соединение пиперидинила в качестве модулятора активности хемокинового рецептора | |
| CY1115118T1 (el) | Διαδικασια για την παρασκευη 5-(2-{[6-(2,2-διφθορο-2-φαινυλαιθοξυ) εξυλ]αμινο}-l-υδροξυαιθυλ)-8-υδροξυκινολιν-2(1η)-ονη | |
| EA201100088A1 (ru) | Пиперидинильное производное как модулятор активности хемокинового рецептора | |
| WO2009107971A3 (ko) | 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도 |